Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for 9 Meters Biopharma, Inc. (NMTR : NSDQ)

• Company Description    9 Meters Biopharma, Inc. is a rare, orphan and unmet needs focused GI company. It's advancing NM-002, a proprietary long-acting GLP-1 agonist into Phase 2 trial for Short Bowel Syndrome, a rare, orphan disease, as well as larazotide, a Phase 3 tight junction regulator being evaluated for patient-reported symptom. 9 Meters Biopharma Inc., formerly known as Innovate Bioph, is based in Raleigh, United States. Number of Employees: 21

• Price / Volume Information    Yesterday's Closing Price: $0.47 Daily Weekly Monthly 20 Day Moving Average: 1,344,328 shares Shares Outstanding: 259.11 (millions) Market Capitalization: $121.78 (millions) Beta: 0.30 52 Week High: $1.55 52 Week Low: $0.35 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 3.16% 16.18% 12 Week -15.04% -6.60% Year To Date -51.98% -46.34%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 8480 HONEYCUTT ROAD SUITE 120 - RALEIGH,NC 27615 USA ph: 919-275-1933 fax: - investor-relations@9meters.com http://www.9meters.com

• General Corporate Information    Officers John Temperato - Chief Executive Officer and President Bethany Sensenig - Chief Financial Officer Lorin K. Johnson - Director Michael T. Constantino - Director Michael Rice - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 654405109 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/11/22 Share - Related Items Shares Outstanding: 259.11 Most Recent Split Date: 2.00 (0.10:1) Beta: 0.30 Market Capitalization: $121.78 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.04 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.17 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/11/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 3.94 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -33.33% vs. Previous Quarter: 0.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/22 - -94.49 12/31/21 - -80.02 09/30/21 - -73.84 ROA 03/31/22 - -80.61 12/31/21 - -69.14 09/30/21 - -63.81 Current Ratio 03/31/22 - 4.75 12/31/21 - 5.91 09/30/21 - 7.76 Quick Ratio 03/31/22 - - 12/31/21 - 5.91 09/30/21 - 7.76 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Book Value 03/31/22 - 0.12 12/31/21 - 0.16 09/30/21 - 0.19 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©